These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 18606661

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.
    Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW.
    J Immunol; 2002 Oct 15; 169(8):4667-73. PubMed ID: 12370407
    [Abstract] [Full Text] [Related]

  • 3. Activation of alloreactive CD8+ T cells operates via CD4-dependent and CD4-independent mechanisms and is CD154 blockade sensitive.
    Zhai Y, Meng L, Busuttil RW, Sayegh MH, Kupiec-Weglinski JW.
    J Immunol; 2003 Mar 15; 170(6):3024-8. PubMed ID: 12626556
    [Abstract] [Full Text] [Related]

  • 4. Alloreactive CD8 T-cell primed/memory responses and accelerated graft rejection in B-cell-deficient sensitized mice.
    Ji H, Shen XD, Gao F, Busuttil RW, Zhai Y, Kupiec-Weglinski JW.
    Transplantation; 2011 May 27; 91(10):1075-81. PubMed ID: 21427633
    [Abstract] [Full Text] [Related]

  • 5. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation.
    Kim EY, Lee EN, Lee J, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Joh JW, Kim SJ.
    Exp Mol Med; 2006 Jun 30; 38(3):284-94. PubMed ID: 16819287
    [Abstract] [Full Text] [Related]

  • 6. CD154 blockade alters innate immune cell recruitment and programs alloreactive CD8+ T cells into KLRG-1(high) short-lived effector T cells.
    Ferrer IR, Wagener ME, Song M, Ford ML.
    PLoS One; 2012 Jun 30; 7(7):e40559. PubMed ID: 22792369
    [Abstract] [Full Text] [Related]

  • 7. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.
    Bishop DK, Chan Wood S, Eichwald EJ, Orosz CG.
    J Immunol; 2001 Mar 01; 166(5):3248-55. PubMed ID: 11207279
    [Abstract] [Full Text] [Related]

  • 8. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway.
    Guo Z, Meng L, Kim O, Wang J, Hart J, He G, Alegre ML, Thistlethwaite JR, Pearson TC, Larsen CP, Newell KA.
    Transplantation; 2001 May 15; 71(9):1351-4. PubMed ID: 11403253
    [Abstract] [Full Text] [Related]

  • 9. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RN.
    J Immunol; 2000 Sep 15; 165(6):3506-18. PubMed ID: 10975872
    [Abstract] [Full Text] [Related]

  • 10. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance.
    Burns AM, Ma L, Li Y, Yin D, Shen J, Xu J, Chong AS.
    J Immunol; 2009 Feb 01; 182(3):1314-24. PubMed ID: 19155477
    [Abstract] [Full Text] [Related]

  • 11. In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy.
    Chen Y, Heeger PS, Valujskikh A.
    J Immunol; 2004 May 01; 172(9):5456-66. PubMed ID: 15100287
    [Abstract] [Full Text] [Related]

  • 12. New insights in CD28-independent allograft rejection.
    Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR.
    Am J Transplant; 2007 Aug 01; 7(8):1917-26. PubMed ID: 17617854
    [Abstract] [Full Text] [Related]

  • 13. B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) mediate CD40-independent help by memory CD4 T cells.
    Gorbacheva V, Ayasoufi K, Fan R, Baldwin WM, Valujskikh A.
    Am J Transplant; 2015 Feb 01; 15(2):346-57. PubMed ID: 25496308
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H, Sayegh MH, Najafian N.
    J Immunol; 2005 Jun 01; 174(11):6648-56. PubMed ID: 15905503
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.